Mode of Death in Heart Failure With Preserved Ejection Fraction

Journal of the American College of Cardiology

Volumn 69, Issue 5, 2017, Pages 556-569

  Vaduganathan, Muthiah ^a   Patel, Ravi B ^b   Michel, Alexander ^c   Shah, Sanjiv J ^b   Senni, Michele ^d   Gheorghiade, Mihai ^b   Butler, Javed ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BAYER PHARMA AG   (Germany)

^d Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^e STONY BROOK UNIVERSITY   (United States)

Author keywords

epidemiology; mortality; outcomes

Indexed keywords

ALDOSTERONE ANTAGONIST; CANDESARTAN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; MEMBRANE METALLOENDOPEPTIDASE; NESIRITIDE; PERINDOPRIL; SPIRONOLACTONE;

AORTA ANEURYSM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HEART RIGHT VENTRICLE FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LUNG EMBOLISM; MULTIPLE ORGAN FAILURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTRICTIVE CARDIOMYOPATHY; REVIEW; SUDDEN CARDIAC DEATH; SUDDEN DEATH; SYSTEMATIC REVIEW; HEART ARRHYTHMIA; HEART FAILURE; HEART STROKE VOLUME; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ARRHYTHMIAS, CARDIAC; CAUSE OF DEATH; DEATH, SUDDEN; HEART FAILURE; HUMANS; STROKE VOLUME;

EID: 85011689133     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.10.078     Document Type: Review

References (58)

1. 1 Ambrosy, A.P., Fonarow, G.C., Butler, J., et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63 (2014), 1123–1133.
2. 2 Butler, J., Fonarow, G.C., Zile, M.R., et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. J Am Coll Cardiol HF 2 (2014), 97–112.
3. 3 Vaduganathan, M., Michel, A., Hall, K., et al. Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail 18 (2016), 54–65.
4. 4 Senni, M., Paulus, W.J., Gavazzi, A., et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 35 (2014), 2797–2815.
5. 5 Greene, S.J., Gheorghiade, M., Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. J Am Coll Cardiol 64 (2014), 1599–1601.
6. 6 Chan, M.M., Lam, C.S., How do patients with heart failure with preserved ejection fraction die?. Eur J Heart Fail 15 (2013), 604–613.
7. 7 Moss, A.J., Hall, W.J., Cannom, D.S., et al. Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335 (1996), 1933–1940.
8. 8 Vaduganathan, M., Patel, R.B., Shah, S.J., et al. Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. Heart Fail Rev 21 (2016), 455–462.
9. 9 Solomon, S.D., Wang, D., Finn, P., et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program [Published correction appears in Circulation 2005;111:378]. Circulation 110 (2004), 2180–2183.
10. 10 Ahmed, A., Rich, M.W., Fleg, J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group trial. Circulation 114 (2006), 397–403.
11. 11 Pitt, B., Pfeffer, M.A., Assmann, S.F., et al., TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
12. 12 Zile, M.R., Gaasch, W.H., Anand, I.S., et al., I-PRESERVE Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) trial. Circulation 121 (2010), 1393–1405.
13. 13 Cleland, J.G., Tendera, M., Adamus, J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 (2006), 2338–2345.
14. 14 Rickenbacher, P., Pfisterer, M., Burkard, T., et al. Why and how do elderly patients with heart failure die? Insights from the TIME-CHF study. Eur J Heart Fail 14 (2012), 1218–1229.
15. 15 Toma, M., Ezekowitz, J.A., Bakal, J.A., et al. The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF trial. Eur J Heart Fail 16 (2014), 334–341.
16. 16 Yamamoto, K., Origasa, H., Hori, M., et al., J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15 (2013), 110–118.
17. 17 Adabag, S., Smith, L.G., Anand, I.S., et al. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail 18 (2012), 749–754.
18. 18 Grigorian-Shamagian, L., Otero Raviña, F., Abu Assi, E., et al. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. Am Heart J 156 (2008), 1184–1190.
19. 19 Hamaguchi, S., Kinugawa, S., Sobirin, M.A., et al., JCARE-CARD Investigators. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J 76 (2012), 1662–1669.
20. 20 Henkel, D.M., Redfield, M.M., Weston, S.A., et al. Death in heart failure: a community perspective. Circ Heart Fail 1 (2008), 91–97.
21. 21 Paulus, W.J., Tschöpe, C., Sanderson, J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007), 2539–2550.
22. 22 Every, N.R., Parsons, L., Hlatky, M.A., et al. Use and accuracy of state death certificates for classification of sudden cardiac deaths in high-risk populations. Am Heart J 134 (1997), 1129–1132.
23. 23 Iribarren, C., Crow, R.S., Hannan, P.J., et al. Validation of death certificate diagnosis of out-of-hospital sudden cardiac death. Am J Cardiol 82 (1998), 50–53.
24. 24 Desai, A.S., McMurray, J.J., Packer, M., et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 36 (2015), 1990–1997.
25. 25 Shah, S.J., Gheorghiade, M., Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 300 (2008), 431–433.
26. 26 Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
27. 27 Butler, J., Braunwald, E., Gheorghiade, M., Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA 312 (2014), 789–790.
28. 28 Fishman, G.I., Chugh, S.S., Dimarco, J.P., et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 122 (2010), 2335–2348.
29. 29 Hinkle, L.E. Jr., Thaler, H.T., Clinical classification of cardiac deaths. Circulation 65 (1982), 457–464.
30. 30 Hicks KA, Hung HMJ, Mahaffey KW, et al., Standardized Data Collection for Cardiovascular Trials Initiative. Standardized definitions for cardiovascular and stroke end point events in clinical trial. CDISC. July 2014. Available at: http://www.cdisc.org/system/files/all/reference_material/application/pdf/Draft%20Definitions%20for%20CDISC%20July%203,%202014.pdf. Accessed December 1, 2016.
31. 31 Shah, S.J., Katz, D.H., Selvaraj, S., et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131 (2015), 269–279.
32. 32 Schelbert, E.B., Piehler, K.M., Zareba, K.M., et al. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J Am Heart Assoc, 4, 2015, e002613.
33. 33 Adabag, S., Rector, T.S., Anand, I.S., et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 16 (2014), 1175–1182.
34. 34 Hicks, K.A., Tcheng, J.E., Bozkurt, B., et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol 66 (2015), 403–469.
35. 35 Narang, R., Cleland, J.G., Erhardt, L., et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17 (1996), 1390–1403.
36. 36 Tseng, Z.H., Hayward, R.M., Clark, N.M., et al. Sudden death in patients with cardiac implantable electronic devices. JAMA Intern Med 175 (2015), 1342–1350.
37. 37 Chugh, S.S., Jui, J., Gunson, K., et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 44 (2004), 1268–1275.
38. 38 Sinha, S.K., Crain, B., Flickinger, K., et al. Clinical inferences of cardiovascular implantable electronic device analysis at autopsy. J Am Coll Cardiol 68 (2016), 1255–1264.
39. 39 Maurer, M.S., Mancini, D., HFpEF: is splitting into distinct phenotypes by comorbidities the pathway forward?. J Am Coll Cardiol 64 (2014), 550–552.
40. 40 Varadhan, R., Weiss, C.O., Segal, J.B., et al. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 48:Suppl (2010), S96–S105.
41. 41 Ushigome, R., Sakata, Y., Nochioka, K., et al. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan – report from the CHART Studies. Circ J 79 (2015), 2396–2407.
42. 42 Kaneko, H., Suzuki, S., Yajima, J., et al. Clinical characteristics and long-term clinical outcomes of Japanese heart failure patients with preserved versus reduced left ventricular ejection fraction: a prospective cohort of Shinken Database 2004-2011. J Cardiol 62 (2013), 102–109.
43. 43 Yap, J., Sim, D., Lim, C.P., et al. Predictors of two-year mortality in Asian patients with heart failure and preserved ejection fraction. Int J Cardiol 183 (2015), 33–38.
44. 44 Liu, M., Chan, C.P., Yan, B.P., et al. Albumin levels predict survival in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 14 (2012), 39–44.
45. 45 Schockmel, M., Agrinier, N., Jourdain, P., et al. Socioeconomic factors and mortality in diastolic heart failure. Eur J Clin Invest 44 (2014), 372–383.
46. 46 Koller, L., Kleber, M., Goliasch, G., et al. C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction. Eur J Heart Fail 16 (2014), 758–766.
47. 47 Senni, M., Gavazzi, A., Oliva, F., et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol 173 (2014), 163–169.
48. 48 Tribouilloy, C., Rusinaru, D., Mahjoub, H., et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 29 (2008), 339–347.
49. 49 Yan, J., Gong, S.J., Li, L., et al. Combination of B-type natriuretic peptide and minute ventilation/carbon dioxide production slope improves risk stratification in patients with diastolic heart failure. Int J Cardiol 162 (2013), 193–198.
50. 50 Lee, D.S., Gona, P., Albano, I., et al. A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail 4 (2011), 36–43.
51. 51 Gottdiener, J.S., McClelland, R.L., Marshall, R., et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 137 (2002), 631–639.
52. 52 Zafrir, B., Paz, H., Wolff, R., et al. Mortality rates and modes of death in heart failure patients with reduced versus preserved systolic function. Eur J Intern Med 22 (2011), 53–56.
53. 53 Zotter-Tufaro, C., Mascherbauer, J., Duca, F., et al. Prognostic significance and determinants of the 6-min walk test in patients with heart failure and preserved ejection fraction. JACC Heart Fail 3 (2015), 459–466.
54. 54 Miyagishima, K., Hiramitsu, S., Kimura, H., et al. Long term prognosis of chronic heart failure: reduced vs preserved left ventricular ejection fraction. Circ J 73 (2009), 92–99.
55. 55 Cenkerova, K., Dubrava, J., Pokorna, V., Kaluzay, J., Jurkovicova, O., Right ventricular systolic dysfunction and its prognostic value in heart failure with preserved ejection fraction. Acta Cardiol 70 (2015), 387–393.
56. 56 Setaro, J.F., Soufer, R., Remetz, M.S., Perlmutter, R.A., Zaret, B.L., Long-term outcome in patients with congestive heart failure and intact systolic left ventricular performance. Am J Cardiol 69 (1992), 1212–1216.
57. 57 Brogan, W.C. 3rd, Hillis, L.D., Flores, E.D., Lange, R.A., The natural history of isolated left ventricular diastolic dysfunction. Am J Med 92 (1992), 627–630.
58. 58 Kupari, M., Lindroos, M., Iivanainen, A.M., Heikkila, J., Tilvis, R., Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med 241 (1997), 387–394.